Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen, Prepping for IPO, Says Revenues Grew 200 Percent Since 2004

NEW YORK (GenomeWeb News) – NimbleGen, which late last week said it has filed for an initial public offering with the Securities and Exchange Commission, said revenues increased 200 percent and that it has accumulated $20 million in net losses over the past three years.
 
In the SEC document, the company said revenues increased from $4.5 million in 2004 to $13.5 million in 2006 on increasing sales. The firm also said grant revenue declined during that period.
 
NimbleGen said it recorded $7 million in net losses in 2006, $5 million in 2005, and $8 million in 2004.
 
The company said R&D spending is focused on new microarrray applications, new software applications, reagents and kits for use with microarrays, and developing Maskless Array Synthesizer, or MAS, systems.
 
NimbleGen said it plans to use the proceeds from the IPO to expand the commercial and marketing infrastructure for its microarray products and services; increase R&D spending on next-generation manufacturing equipment; increase production capacity, and pay for general expenses.
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.